JSKN021 not checked

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“JSKN021 administered intravenously at selected dose levels according to protocol”In the company’s words, NCT07617727 on ClinicalTrials.gov
Tested for
Advanced Malignant Solid Tumors
Main trialPhase 1
“This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.”In the company’s words, NCT07617727 on ClinicalTrials.gov

Other drugs for Advanced Malignant Solid Tumors

All 2440 drugs for Advanced Malignant Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Oct 2028 A Phase I Study of JSKN021 in Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JSKN021

Following is part of Solo: you see every change to JSKN021 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in